Looking for transparency
Dr. Tero-Pekka Alastalo discusses how sequencing technologies and the chosen strategy in a lab can define quality and yield, highlighting bioinformatics and interpretation as being the biggest challenges in the current market. He also discusses what can make a lab transparent in its services and what is not transparent. Finally, Blueprint Genetics’ experiences with rare disease will be reported by presenting the recent analytic validation results of our diagnostic pipeline and the yields that we have encountered from different panels.
You can find our comprehensive analytic validation here!